Not provided
Not provided
Not provided
Not provided
Not provided
Placebo - Active Drug Not Available. No patients received drug. There are no study results to disclose.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess if a single dose of Diclofenac potassium (0.5 mg/kg) is more or as effective as a single dose of Acetaminophen (10 mg/kg) in the reduction of fever during 2 hours, in the treatment of febrile children with acute upper respiratory infections.
This is a comparative double blind, double dummy, randomized study on the effectiveness of Diclofenac potassium versus Acetaminophen in febrile children with acute upper respiratory tract infections. The patient will be randomized to either group: Group A (Diclofenac potassium (0.5 mg/kg) or Group B (Acetaminophen (10 mg/kg)). A Health Care Professional trained will measure the temperature during 2 hours. During the study period, parents or legal representatives will be invited to fill a survey about the habits and knowledge regarding fever management at home.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diclofenac potassium | Experimental |
| |
| Acetaminophen | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diclofenac potassium | Drug | Diclofenac potassium |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The Reduction of Temperature | 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Reach a Reduction of Temperature as 0.5 and 1 °C | 2 hours | |
| Time With a Temperature ≤ 38,4 °C in a Period of 6 Hours | 6 hours | |
| Safety of Diclofenac Potassium Therapy in the Study Period |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de niños "J. M. de los Rios", Distrito Metropolitano | Caracas | Venezuela | ||||
| Ciudad Hospitalaria Enrique Tejera, Valencia |
Not provided
2 participants entered the study but did not receive drug because drug was not available in the region. The study was then terminated.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Diclofenac Potassium | This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region |
| FG001 | Acetaminophen | This study was cancelled. No patients were enrolled in this group. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Diclofenac Potassium | This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region |
| BG001 | Acetaminophen | This study was cancelled. No patients were enrolled in this group. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Reduction of Temperature | Posted | 2 hours |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Diclofenac Potassium | This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region |
Not provided
Not provided
This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 862-778-8300 |
Not provided
| ID | Term |
|---|---|
| D005334 | Fever |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004008 | Diclofenac |
| D000082 | Acetaminophen |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Acetaminophen |
| Drug |
Acetaminophen |
|
| 6 hours |
| The Level of Knowledge That Parents or Legal Representatives Have on the Treatment of Fever | 2 hours |
| Estado Carabobo |
| Venezuela |
| BG002 | Total | Total of all reporting groups |
| Mean |
| Standard Deviation |
| years |
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Secondary | Time to Reach a Reduction of Temperature as 0.5 and 1 °C | Not Posted | 2 hours |
| Secondary | Time With a Temperature ≤ 38,4 °C in a Period of 6 Hours | Not Posted | 6 hours |
| Secondary | Safety of Diclofenac Potassium Therapy in the Study Period | Not Posted | 6 hours |
| Secondary | The Level of Knowledge That Parents or Legal Representatives Have on the Treatment of Fever | Not Posted | 2 hours |
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Acetaminophen | This study was cancelled. No patients were enrolled in this group. | 0 | 0 | 0 | 0 |
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.
| D000083 |
| Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D000814 | Aniline Compounds |
| D000588 | Amines |